Haploidentical hematopoietic transplantation represents a curative option for certain patients with advanced hematological neoplasms.
1,2 T-cell depletion or post-transplant CY abrogates risks of GVHD but may impair engraftment, post-transplant immune reconstitution or graft-versustumor effects. [3] [4] [5] We incorporated the immunosuppressive sirolimus into a nonmyeloablative regimen for T-cell replete transplantation of haplotype-mismatched progenitor cells in 17 patients without other suitable donors.
Fludarabine (25 mg/m 2 ) was administered i.v. from days À7 to À3 (five total doses) and CY (1000 mg/m 2 ) was administered i.v. on days À7 and À6. Sirolimus was administered on day À7 and tacrolimus on day À4 (both at 5-10 ng/ml). Tacrolimus was continued until at least day 30 and sirolimus until at least day 100. Equine antithymocyte globulin (30 mg/m 2 ) (with methylprednisolone premedication) was given on days À1, þ 1, þ 3 and þ 5 and MTX (5 mg/m 2 ) was administered i.v. on days þ 1, þ 3 and þ 6. Haploidentical (3 or 4/6 HLA antigens matching) G-CSF-mobilized progenitor cells were infused unmanipulated.
Patients were older (median age 56 years) and heavily pretreated. Characteristics and outcomes are shown in Table 1 . All 17 engrafted stably. Chimerism was complete in 14 of 17 (82%) patients by day 90. All achieved neutrophils (ANC4500) by day 18, and in 11 of 17 patients. platelets were 450 000/ml by day 60.
Acute GVHD occurred in 14 of 17 (82%) patients, resulting in the death of six patients. GVHD was grade 1-2 in 11 of 14 patients and grade 3 in 3 of 14 patients. In 11 of 17 patients, creatinine rose above 2.0 mg per 100 ml but renal insufficiency was only brief and reversible. One patient was briefly hemodialyzed. Lactate dehydrogenase and platelets were assessed biweekly, but significant thrombotic microangiopathy occurring in only one patient (managed with reduced tacrolimus dose). Only 3 of 17 patients developed opportunistic infections before day 100, and there was one case each of pulmonary aspergillus, varicella and human herpes virus-6. Invasive CMV infections were not observed, but two developed CMV reactivation.
Antitumor effects were apparent, with CR developing in four of five patients conditioned with refractory leukemia (progression-free survival of 37, 58, 210 and 295 days) and three of six patients with active lymphoma (50%). Patient no. 7 is alive on day 1076 without active Hodgkin's disease, and patient no. 6 survived 975 days without progression of lymphoma but succumbed to stroke. Patient no. 3 survived 1563 days after transplant given in second remission of AML.
These observations confirm data suggesting that haploidentical transplantation may yield long-term control of leukemias and lymphomas through graftversus-tumor effects. Our data are notable for the use of sirolimus, the consistent engraftment achieved and the long follow-up of survivors. The immunosuppressive sirolimus promotes tolerance in mismatched experimental transplantation 6 and is successfully used for human matched 
